Abstract:Context Previous findings regarding the relationship between smoking and clopidogrel effects were considerably discrepant. Objective To assess the impact of smoking on clinical and pharmacodynamic response to clopidogrel. Data sources Medline, EMBASE and the Cochrane Library through January 2013 were searched. Reference lists of pertinent literatures and abstracts of major cardiovascular conferences were screened. Study selection Clinical and laboratory studies, which reported major adverse cardiovascular events and on-clopidogrel platelet reactivity categorised by smoking status respectively, were selected. Data extraction Descriptive and quantitative data were extracted. The main analyses were performed under a random-effects model. For clinical studies, HR estimates were synthesised according to smoking status; for laboratory studies, standardised mean difference (SMD) of on-clopidogrel platelet reactivity and OR for high on-clopidogrel platelet reactivity were pooled. Heterogeneity was quantified by computing I2 statistic. Results Of the 1869 citations retrieved, seven clinical studies and 12 laboratory studies involving 111 132 patients with established cardiovascular disease and 6658 patients with acute coronary syndrome and/or stent deployment, respectively, were included for meta-analysis. Pooled clinical results showed that an intensified antiplatelet regimen involving clopidogrel was associated with 10% reduced risk for major adverse cardiovascular events among non-current smokers (HR 0.90; 95% CI 0.85 to 0.96), while this clinical benefit was enhanced by 2.9-fold among current smokers (HR 0.71; 95% CI 0.62 to 0.80). Pooled analysis of laboratory studies revealed that current smokers had significantly lower on-clopidogrel platelet reactivity (SMD −0.30; 95% CI −0.46 to −0.15) but, notably, there was considerable inter-study heterogeneity (I2 76.2%; p=0.000). The analysis based on four studies (n=1423) suggested a significantly lower odds of high on-clopidogrel platelet reactivity among current smokers than those among never smokers (OR 0.33; 95% CI 0.22 to 0.43). Conclusions Smoking appears to positively modify the relative clinical efficacy and pharmacodynamic effects of clopidogrel.

Smoking as a risk factor for lower extremity peripheral artery disease in women compared to men: A systematic review and meta-analysis

Gender susceptibility for cigarette smoking-attributable lung cancer: a systematic review and meta-analysis.

Smoking and Risk of Venous Thromboembolism: A Systematic Review

Research of the Relationship Between Smoking and Peripheral Arterial Disease

Sex-specific risk of smoking for abdominal aortic aneurysm and exploration of potential mechanism: meta-analysis and prospective cohort study

Smoking and the Pathophysiology of Peripheral Artery Disease

Combined Effects of Smoking and Peripheral Arterial Disease on All-Cause and Cardiovascular Disease Mortality in a Chinese Male Cohort.

Effectiveness and Safety of Platelet ADP -P2Y12 Receptor Inhibitors Influenced by Smoking Status: A Systematic Review and Meta-Analysis.

Sex-Specific Associations of Smoking with Spontaneous Subarachnoid Hemorrhage: Findings from Observational Studies

Cigarette smoking as a risk factor for type 2 diabetes in women compared with men: a systematic review and meta-analysis of prospective cohort studies.

Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis

Sex differences in the prevalence of peripheral artery disease in patients undergoing coronary catheterization

The Effect of Smoking on Residual Platelet Reactivity to Clopidogrel: a Systematic Review and Meta-Analysis

Women with Peripheral Arterial Disease Experience Faster Functional Decline Than Men with Peripheral Arterial Disease

Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease.

Smoking and Risk of Erectile Dysfunction: Systematic Review of Observational Studies with Meta-Analysis.

ENVIRONMENT-WIDE ASSOCIATION STUDY TO IDENTIFY NOVEL FACTORS ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE: EVIDENCE FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (1999-2004)

Global disease burden and its attributable risk factors of peripheral arterial disease

The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.

Associations of smoking status with carotid atherosclerosis: Mediated role of blood indexes and blood pressure

THE IMPACTS OF SMOKING ON CLINICAL EFFICACY AND PHARMACODYNAMIC EFFECTS OF CLOPIDOGREL: A SYSTEMATIC REVIEW AND META–ANALYSIS